NKGen Biotech, Inc. Common Stock(NKGN)Earnings, Financials & Key Ratios

NKGN•NASDAQ

$0.06

Price updated Jul 2, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryCommercial Specialty Pharma

AboutGraf Acquisition Corp. IV does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. Graf Acquisition Corp. IV was incorporated in 2021 and is based in The Woodlands, Texas.Show more

Revenue$0
EBITDA-$27M+5.5%
Net Income-$44M+46.6%
EPS (Diluted)-1.54+71.4%

NKGN Price & Volume

NKGen Biotech, Inc. Common Stock (NKGN) stock price & volume — 10-year historical chart

Loading chart...

Clinical Development Costs Outpace Liquidity Reserves

Investment Thesis • Updated 2025Q1

VerdictNegative

Growth:Mixed

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Clinical Trial Funding Dependency

Key Thesis Takeaways

NKGen Biotech operates as a pre-revenue clinical-stage entity, with its valuation entirely contingent upon the success of its SNK01 cell therapy platform.
The company faces significant financial headwinds, characterized by a persistent reliance on external capital and a precarious balance sheet with a current ratio of 0.05.
Investors should monitor the firm's ability to secure additional funding, as the current trajectory of negative free cash flow and rising debt levels suggests substantial long-term solvency risks.

Verdict Logic

the company's critical liquidity position, highlighted by a current ratio of 0.05 and a $50.3 million equity deficit, suggests an imminent risk of capital exhaustion that outweighs potential clinical upside.

NKGN Growth Metrics

NKGen Biotech, Inc. Common Stock (NKGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years-

TTM-

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM70.56%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM69.63%

Return on Capital

10 Years-659.92%

5 Years-659.92%

3 Years-929.46%

Last Year-326.76%

Latest NKGN News

Recent stock market news and headlines for NKGen Biotech, Inc. Common Stock (NKGN)

GlobeNewsWire·3 days ago

NKGen Biotech to Present at the 2026 BIOCHINA Global Forum on Troculeucel's Potential in Alzheimer's Disease and Other Neurodegenerative Conditions

SANTA ANA, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that NKGen Chairman and Chief Executive Officer Paul Y. Song, M.D., will present on the Company's lead investigational program, troculeucel, at the 2026 BIOCHINA Global Forum, taking place July 9–10, 2026, in Seoul, South Korea.

Globe News Wire·3 days ago

NKGen Biotech to Present at the 2026 BIOCHINA Global Forum on Troculeucel’s Potential in Alzheimer’s Disease and Other Neurodegenerative Conditions

SANTA ANA, Calif. , July 02, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced that NKGen Chairman and Chief Executive Officer Paul Y.

Peers Comparison

Key metrics vs top competitors for NKGen Biotech, Inc. Common Stock (NKGN)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
NKGNNKGen Biotech, Inc. Common StockCurrent	$0.06	$3.08M	-0.04	—	—	—	—
FATEFate Therapeutics, Inc.	$3.02	$352.01M	-2.63	-51.24%	-2056.79%	-58.89%	—
NKTXNkarta, Inc.	$2.85	$203.9M	-2.02	—	—	-30.9%	—
CELCCelcuity Inc.	$104.49	$5.1B	-27.64	—	—	-244.61%	—
STTKShattuck Labs, Inc.	$6.51	$311.85M	-9.30	-82.52%	-4987.4%	-60.73%	—
AGENAgenus Inc.	$3.41	$142M	-1002.94	10.37%	52.16%	—	—

Compare NKGN vs Peers

NKGen Biotech, Inc. Common Stock (NKGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs FATE

Most directly comparable listed peer for NKGN.

Scale Benchmark

vs AMGN

Larger-name benchmark to compare NKGN against a more recognizable public peer.

Peer Set

Compare Top 5

vs FATE, NKTX, CELC, STTK

Get notified when NKGN posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

NKGN Frequently Asked Questions

NKGen Biotech, Inc. Common Stock (NKGN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is NKGen Biotech, Inc. Common Stock's revenue?

NKGen Biotech, Inc. Common Stock (NKGN) reported $0.7M in revenue for fiscal year 2024. This represents a 53% increase from $0.4M in 2021.

Is NKGN profitable?

NKGen Biotech, Inc. Common Stock (NKGN) reported a net loss of $23.6M for fiscal year 2024.

Dividend & Returns

What is NKGen Biotech, Inc. Common Stock's free cash flow?

NKGen Biotech, Inc. Common Stock (NKGN) had negative free cash flow of $19.7M in fiscal year 2024, likely due to heavy capital investments.

What if you invested $1,000 in NKGN back in 2021?

Total return calculator · dividends reinvested · 5+ years of data

See returns →

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

NKGNNKGen Biotech, Inc. Common StockCurrent

$0.06

$3.08M

-0.04

—

FATEFate Therapeutics, Inc.

$3.02

$352.01M

-2.63

-51.24%

-2056.79%

-58.89%

—

NKTXNkarta, Inc.

$2.85

$203.9M

-2.02

—

-30.9%

—

CELCCelcuity Inc.

$104.49

$5.1B

-27.64

—

-244.61%

—

STTKShattuck Labs, Inc.

$6.51

$311.85M

-9.30

-82.52%

-4987.4%

-60.73%

—

AGENAgenus Inc.

$3.41

$142M

-1002.94

10.37%

52.16%

—